Pediatric type diffusely infiltrating gliomas will be recognized regardless of patient’s age, marked by a host of markers that are possible targets (low grade: FGFr1 mutants, BRAF pV600E mutant; high grade: H3K27 altered, H3-G24 mutant), and H3 wild-type plus IDH wild-type diffuse pediatric gliomas that have multiple characterized molecular pathways often involving amplifications (PDGFRA, EGFR, MYCN). Here, PDGFRA is linked to central nervous system cancer.